|
  
- 积分
- 0
- 威望
- 0
- 包包
- 3465
|
Weintraub/Elsevier1 D' P3 F/ _, w2 L
' H7 c3 {. }+ z& U
Rapidly dividing cells such as tumor cells are susceptible to DNA damage that then induces apoptosis. As a result, DNA-damaging chemicals such as cisplatin are used as anticancer treatments. How the majority of nontumor cells survive chemotherapy has been mysterious. The trivial explanation is that the cells are growth-arrested and thus less susceptible to DNA-damaging agents. But a more precise explanation is put forth in a new article by Benjamin Deverman, Steven Weintraub (Washington University, St. Louis, MO), and colleagues, who have identified an antiapoptotic activity necessary to keep damaged but nondividing cells alive.
2 d% M+ M2 {" z0 @* n
& n" o: A0 [: g! N6 A$ {, |5 |6 hThe proapoptotic activity that allows tumor cells to die is an unusual modification of the antiapoptotic protein Bcl-xL caused by DNA-damaging agents. This modification, deamidation of two asparagine residues, inactivated Bcl-xL, thereby allowing cell death to proceed. Growth-arrested cells escaped apoptosis by blocking deamidation. To prevent deamidation, cells needed Rb, a tumor suppressor protein that inhibits cell cycle progression. Because tumor cells lack Rb, and cycling cells down-regulate Rb, they are more sensitive to DNA-damaging agents. "Deamidation is like a checkpoint," says Weintraub. "If you undergo DNA damage in the absence of Rb, then cells are susceptible to death."
/ [) e6 |, [) J: l7 d. P. f! A: Q8 ^! i
Reference:1 x0 c, b9 g0 [1 m
2 s7 S8 \ j3 v2 dDeverman, B., et al. 2002. Cell. 111:51–62.(Bcl-xL modification by cisplatin is bloc) |
|
发表于 2009-3-6 00:07
发表于 2015-6-4 20:41
